Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia.

Pubmed ID: 34730265

Pubmed Central ID: PMC10535364

Journal: European journal of heart failure

Publication Date: Jan. 1, 2022

Affiliation: Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.

MeSH Terms: Humans, Adult, Risk Factors, Cohort Studies, Risk Assessment, Heart Failure, Natriuretic Peptides, Glucose Metabolism Disorders

Grants: R03 AG067960

Authors: Butler J, Fonarow GC, Pandey A, Tang WHW, Wang TJ, Vaduganathan M, Everett BM, Patel KV, Segar MW, McGuire DK, Kannan V, Willett D, Khan MS, Peterson E

Cite As: Segar MW, Khan MS, Patel KV, Vaduganathan M, Kannan V, Willett D, Peterson E, Tang WHW, Butler J, Everett BM, Fonarow GC, Wang TJ, McGuire DK, Pandey A. Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. Eur J Heart Fail 2022 Jan;24(1):169-180. Epub 2021 Nov 23.

Studies:

Abstract

AIMS: To evaluate the performance of the WATCH-DM risk score, a clinical risk score for heart failure (HF), in patients with dysglycaemia and in combination with natriuretic peptides (NPs). METHODS AND RESULTS: Adults with diabetes/pre-diabetes free of HF at baseline from four cohort studies (ARIC, CHS, FHS, and MESA) were included. The machine learning- [WATCH-DM(ml)] and integer-based [WATCH-DM(i)] scores were used to estimate the 5-year risk of incident HF. Discrimination was assessed by Harrell's concordance index (C-index) and calibration by the Greenwood-Nam-D'Agostino (GND) statistic. Improvement in model performance with the addition of NP levels was assessed by C-index and continuous net reclassification improvement (NRI). Of the 8938 participants included, 3554 (39.8%) had diabetes and 432 (4.8%) developed HF within 5 years. The WATCH-DM(ml) and WATCH-DM(i) scores demonstrated high discrimination for predicting HF risk among individuals with dysglycaemia (C-indices = 0.80 and 0.71, respectively), with no evidence of miscalibration (GND P ≥0.10). The C-index of elevated NP levels alone for predicting incident HF among individuals with dysglycaemia was significantly higher among participants with low/intermediate (<13) vs. high (≥13) WATCH-DM(i) scores [0.71 (95% confidence interval 0.68-0.74) vs. 0.64 (95% confidence interval 0.61-0.66)]. When NP levels were combined with the WATCH-DM(i) score, HF risk discrimination improvement and NRI varied across the spectrum of risk with greater improvement observed at low/intermediate risk [WATCH-DM(i) <13] vs. high risk [WATCH-DM(i) ≥13] (C-index = 0.73 vs. 0.71; NRI = 0.45 vs. 0.17). CONCLUSION: The WATCH-DM risk score can accurately predict incident HF risk in community-based individuals with dysglycaemia. The addition of NP levels is associated with greater improvement in the HF risk prediction performance among individuals with low/intermediate risk than those with high risk.